Escherichia coli - Revision history

Elcatracho: /* Background */

2022-01-05T08:37:43Z

Background

2021-02-21T01:37:42Z

Background

2019-10-16T17:44:29Z

← Older revision		Revision as of 17:44, 16 October 2019
Line 17:		Line 17:
	**[[Ciprofloxacin]] may increase enterotoxin release		**[[Ciprofloxacin]] may increase enterotoxin release
	*7-14 days after infection, highest risk for HUS, which may need follow up and monitoring of:		*7-14 days after infection, highest risk for HUS, which may need follow up and monitoring of:
	**Proteinuria		**[[Proteinuria]]
	**[[Hematuria]]		**[[Hematuria]]
	**Red cell casts		**Red cell casts

2016-08-11T10:09:59Z

Text replacement - "Cr " to "Creatinine "

← Older revision		Revision as of 10:09, 11 August 2016
Line 20:		Line 20:
	**[[Hematuria]]		**[[Hematuria]]
	**Red cell casts		**Red cell casts
	**Cr elevation		**Creatinine elevation
	===[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>===		===[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>===
	{\| class="wikitable"		{\| class="wikitable"

2016-07-25T03:18:28Z

Text replacement - "==Diagnosis==" to "==Evaluation=="

2016-07-13T23:53:20Z

Text replacement - "f/u" to "follow up"

← Older revision		Revision as of 23:53, 13 July 2016
Line 16:		Line 16:
	**Antibiotics do not alleviate symptoms, reduce carrier risk of organism, or reduce [[HUS]] risk		**Antibiotics do not alleviate symptoms, reduce carrier risk of organism, or reduce [[HUS]] risk
	**[[Ciprofloxacin]] may increase enterotoxin release		**[[Ciprofloxacin]] may increase enterotoxin release
	*7-14 days after infection, highest risk for HUS, which may need ~~f/u~~ and monitoring of:		*7-14 days after infection, highest risk for HUS, which may need follow up and monitoring of:
	**Proteinuria		**Proteinuria
	**[[Hematuria]]		**[[Hematuria]]

2016-07-13T23:27:53Z

← Older revision		Revision as of 23:27, 13 July 2016
Line 14:		Line 14:
	*'''Supportive only'''		*'''Supportive only'''
	*Do not treat with antibiotics (typically the same for ETEC)		*Do not treat with antibiotics (typically the same for ETEC)
	**~~Abx~~ do not alleviate ~~sxs~~, reduce carrier risk of organism, or reduce HUS risk		**Antibiotics do not alleviate symptoms, reduce carrier risk of organism, or reduce [[HUS]] risk
	**Ciprofloxacin may increase enterotoxin release		**[[Ciprofloxacin]] may increase enterotoxin release
	*7-14 days after infection, highest risk for HUS, which may need f/u and monitoring of:		*7-14 days after infection, highest risk for HUS, which may need f/u and monitoring of:
	**Proteinuria		**Proteinuria
	**Hematuria		**[[Hematuria]]
	**Red cell casts		**Red cell casts
	**Cr elevation		**Cr elevation

2016-02-20T23:31:22Z

← Older revision		Revision as of 23:31, 20 February 2016
Line 13:		Line 13:
	Infection by Escherichia coli O157:H7 and Other Enterohemorrhagic E. coli (EHEC). Merck Manual. http://www.merckmanuals.com/professional/infectious-diseases/gram-negative-bacilli/infection-by-escherichia-coli-o157,-c-,h7-and-other-enterohemorrhagic-e,-d-,-coli-(ehec)</ref>==		Infection by Escherichia coli O157:H7 and Other Enterohemorrhagic E. coli (EHEC). Merck Manual. http://www.merckmanuals.com/professional/infectious-diseases/gram-negative-bacilli/infection-by-escherichia-coli-o157,-c-,h7-and-other-enterohemorrhagic-e,-d-,-coli-(ehec)</ref>==
	*'''Supportive only'''		*'''Supportive only'''
	*Do not treat with antibiotics		*Do not treat with antibiotics (typically the same for ETEC)
	**Abx do not alleviate sxs, reduce carrier risk of organism, or reduce HUS risk		**Abx do not alleviate sxs, reduce carrier risk of organism, or reduce HUS risk
	**Ciprofloxacin may increase enterotoxin release		**Ciprofloxacin may increase enterotoxin release

2016-02-20T23:28:09Z

← Older revision		Revision as of 23:28, 20 February 2016
Line 10:		Line 10:
	*Rapid assay for Shiga toxin		*Rapid assay for Shiga toxin

	==Management<ref>Bush LM and Perez MT.		==Management of EHEC<ref>Bush LM and Perez MT.
	Infection by Escherichia coli O157:H7 and Other Enterohemorrhagic E. coli (EHEC). Merck Manual. http://www.merckmanuals.com/professional/infectious-diseases/gram-negative-bacilli/infection-by-escherichia-coli-o157,-c-,h7-and-other-enterohemorrhagic-e,-d-,-coli-(ehec)</ref>==		Infection by Escherichia coli O157:H7 and Other Enterohemorrhagic E. coli (EHEC). Merck Manual. http://www.merckmanuals.com/professional/infectious-diseases/gram-negative-bacilli/infection-by-escherichia-coli-o157,-c-,h7-and-other-enterohemorrhagic-e,-d-,-coli-(ehec)</ref>==
	*'''Supportive only'''		*'''Supportive only'''

2016-02-20T23:27:22Z

← Older revision		Revision as of 23:27, 20 February 2016
Line 10:		Line 10:
	*Rapid assay for Shiga toxin		*Rapid assay for Shiga toxin

	==Management==		==Management<ref>Bush LM and Perez MT.
			Infection by Escherichia coli O157:H7 and Other Enterohemorrhagic E. coli (EHEC). Merck Manual. http://www.merckmanuals.com/professional/infectious-diseases/gram-negative-bacilli/infection-by-escherichia-coli-o157,-c-,h7-and-other-enterohemorrhagic-e,-d-,-coli-(ehec)</ref>==
			*'''Supportive only'''
			*Do not treat with antibiotics
			**Abx do not alleviate sxs, reduce carrier risk of organism, or reduce HUS risk
			**Ciprofloxacin may increase enterotoxin release
			*7-14 days after infection, highest risk for HUS, which may need f/u and monitoring of:
			**Proteinuria
			**Hematuria
			**Red cell casts
			**Cr elevation
	===[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>===		===[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>===
	{\| class="wikitable"		{\| class="wikitable"